Difference between revisions of "Team:ETH Zurich"

 
(35 intermediate revisions by 6 users not shown)
Line 10: Line 10:
 
<main>
 
<main>
  
−
<div id="wrap">
+
<div class="banner">
−
test
+
<figure class="banner" id="banner">
−
</div>
+
−
 
+
−
<figure class="fig-nonfloat" id="banner">
+
 
     <img src="https://static.igem.org/mediawiki/2017/c/c3/T--ETH_Zurich--Banner.png" alt="CATE" />
 
     <img src="https://static.igem.org/mediawiki/2017/c/c3/T--ETH_Zurich--Banner.png" alt="CATE" />
 
</figure>
 
</figure>
Line 24: Line 21:
 
</a>
 
</a>
 
<figure>
 
<figure>
 +
</div>
  
 +
<section id="scrollstart"></section>
  
−
 
−
<section id="scrollstart"></section>
 
 
<section id="start" class="step">
 
<section id="start" class="step">
−
     <div class="why" id="first">
+
     <div class="why">
 
     <h1>WHY</h1>
 
     <h1>WHY</h1>
−
         <p>Cancer kills over 8 million people every year. That's the entire population of Switzerland!</p>
+
         <p>Cancer kills over 8 million people every year. That's as much as the entire population of Switzerland!</p>
 
         <p>We need more specific therapies because current approaches result in many side-effects. That's why we invented <span title="Came close to being FUSBa (<yyyeaah no ;))">CATE</span>, the first all-in-one living cancer therapeutic with an integrated two-step safety mechanism.
 
         <p>We need more specific therapies because current approaches result in many side-effects. That's why we invented <span title="Came close to being FUSBa (<yyyeaah no ;))">CATE</span>, the first all-in-one living cancer therapeutic with an integrated two-step safety mechanism.
 
         <p>A living cure to a living disease!</p>
 
         <p>A living cure to a living disease!</p>
 
         <br>
 
         <br>
−
         <p><button><a href="https://2017.igem.org/Team:ETH_Zurich/Background" class="more"> BACKGROUND</a></button></p>
+
         <p><a href="https://2017.igem.org/Team:ETH_Zurich/Description" class="more"> BACKGROUND</a></p>
 
     </div>
 
     </div>
 
</section>
 
</section>
Line 49: Line 46:
 
<br>
 
<br>
 
     <h1>VISION</h1>
 
     <h1>VISION</h1>
−
         <p>CATE consists of the non-pathogenic bacterium <span class="bacterium">E. coli</span> Nissle that has the intrinsic ability to home preferentially in tumors.</p>
+
         <p>To tackle the challenge of treating cancer, we decided to look beyond classical approaches and from the point of view of a synthetic biologist. </p>
−
         <p>It features two safety checkpoint mechanisms to ensure only tumor cells are damaged.</p>
+
         <p>Our search led us to the concept of bacterial cancer therapy.</p>
 
         <br>
 
         <br>
−
         <p><button><a href="https://2017.igem.org/Team:ETH_Zurich/Description" class="more">Description</a></button></p>
+
         <p><a href="https://2017.igem.org/Team:ETH_Zurich/Description" class="more">STORY OF CATE</a></p>
 
     </div>
 
     </div>
  
Line 66: Line 63:
 
<section id="third" class="step">
 
<section id="third" class="step">
 
     <div>
 
     <div>
 +
        <p>CATE consists of the non-pathogenic bacterium <span class="bacterium">E. coli</span> Nissle that has the intrinsic ability to home preferentially in tumors.</p>
 +
        <p>It features two safety checkpoint mechanisms to ensure only tumor cells are damaged.</p>
 
         <p>CATE is administered intravenously, travels through the blood and colonizes tumors. When enough bacteria have accumulated in the tumor, they make themselves visible and  
 
         <p>CATE is administered intravenously, travels through the blood and colonizes tumors. When enough bacteria have accumulated in the tumor, they make themselves visible and  
 
       start preparing the cytotoxic payload.</p>  
 
       start preparing the cytotoxic payload.</p>  
−
         <p> After imaging the tumor with MRI, the doctor can then activate release of the cancer-killing payload. </p>
+
         <p> After imaging the tumor with MRI, the doctor can then activate the release of the cancer-killing payload. </p>
 
         <br>
 
         <br>
−
         <p><button><a href="https://2017.igem.org/Team:ETH_Zurich/Applied_Design" class="more">Treatment</a></button></p>
+
         <p><a href="https://2017.igem.org/Team:ETH_Zurich/Applied_Design" class="more">CATE IN ACTION</a></p>
 
     </div>
 
     </div>
  
Line 78: Line 77:
 
</figure>
 
</figure>
 
</section>
 
</section>
 +
 +
  
 
<div class="space">
 
<div class="space">
Line 85: Line 86:
 
<section id="fourth" class="step">
 
<section id="fourth" class="step">
 
<div class="circuit">
 
<div class="circuit">
 +
<br>
 +
<br>
 +
<br>
 
<figure class="andgate">
 
<figure class="andgate">
 
   <img src="https://static.igem.org/mediawiki/2017/8/8c/T--ETH_Zurich--ANDgate.png">
 
   <img src="https://static.igem.org/mediawiki/2017/8/8c/T--ETH_Zurich--ANDgate.png">
 
</figure>
 
</figure>
 
     <div>
 
     <div>
−
         <p>To achieve all these novel functions, we designed a genetic circuit that is distributed over two de novo synthesized DNA molecules.</p>
+
 
 +
         <p>To achieve all these novel functions, we designed a genetic circuit that is distributed over two synthetic DNA sequences.</p>
 
         <p> All functions were tested and optimized to make the resulting circuit as safe and well-characterized as possible.</p>
 
         <p> All functions were tested and optimized to make the resulting circuit as safe and well-characterized as possible.</p>
 
         <br>
 
         <br>
−
       <p><button><a href="https://2017.igem.org/Team:ETH_Zurich/Circuit" class="more">Circuit</a></button></p>
+
       <p><a href="https://2017.igem.org/Team:ETH_Zurich/Circuit" class="more">CIRCUIT</a></p>
 
     </div>
 
     </div>
 
</section>
 
</section>
Line 104: Line 109:
 
<br>
 
<br>
 
<h1>ENGINEERING</h1>
 
<h1>ENGINEERING</h1>
−
         <p>We increased the understanding of the system's underlying mathematics by simulating the functions with models.</p><p> The models were then used to define important questions to clarify in experiments and develop efficient design strategies.</p>
+
         <p>We increased the understanding of the system's underlying mathematics by simulating its behavior with our models.</p><p> The models were then used to define important questions to clarify in experiments and develop efficient experimental and genetic design strategies.</p>
 
         <br>
 
         <br>
−
         <p><button><a href="https://2017.igem.org/Team:ETH_Zurich/Dry_Lab" class="more">Dry Lab</a></button></p>
+
         <p><a href="https://2017.igem.org/Team:ETH_Zurich/Model" class="more">DRY LAB</a></p>
 
   </div>
 
   </div>
 
</section>
 
</section>
Line 119: Line 124:
 
         <p>Experimentally, we collected data to support and refine our models and to show that our system works.</p>
 
         <p>Experimentally, we collected data to support and refine our models and to show that our system works.</p>
 
         <br>
 
         <br>
−
         <p><button><a href="https://2017.igem.org/Team:ETH_Zurich/Experiments" class="more">Wet Lab</a></button></p>
+
         <p><a href="https://2017.igem.org/Team:ETH_Zurich/Experiments" class="more">WET LAB</a></p>
 
     </div>
 
     </div>
 
</section>
 
</section>
Line 130: Line 135:
 
</figure>
 
</figure>
 
     <h1>ACHIEVEMENTS</h1>
 
     <h1>ACHIEVEMENTS</h1>
−
         <p>We could experimentally confirm the predictions of the models. After testing every function individually, we combined them one after the other in milestone experiments to show the system in action.</p> <p> We created and characterized new BioBrick parts that are important for the iGEM competition and are freely for the future iGEM teams.</p>
+
         <p>We could experimentally confirm the predictions of the models. After testing every function individually, we combined them one after the other in milestone experiments to show the system in action.</p> <p> We created and characterized new BioBrick parts as a contribution for the synthetic biology community.</p>
 
         <br>
 
         <br>
−
         <p><button><a href="https://2017.igem.org/Team:ETH_Zurich/Results" class="more">Achievements</a></button></p>
+
         <p><a href="https://2017.igem.org/Team:ETH_Zurich/Results" class="more">ACHIEVEMENTS</a></p>
 
     </div>
 
     </div>
 
</section>
 
</section>
Line 140: Line 145:
 
   <div class="HP">
 
   <div class="HP">
 
     <h1>HUMAN PRACTICES</h1>
 
     <h1>HUMAN PRACTICES</h1>
−
     <div>
+
<figure class="HP">
−
         <p>We went beyond the lab and reached out to experts to better understand current technological and safety issues in order to enhance the design of our project. Further, we           
+
     <img src="https://static.igem.org/mediawiki/2017/4/4a/T--ETH_Zurich--HPlanding.png">
 +
</figure>
 +
         <p>We went beyond the lab and reached out to experts to better understand current technological and safety issues in order to enhance the design of our project.</p><p> Further, we           
 
         introduced our project and the field of synthetic biology to the general public and together explored issues related to safety, ethics and sustainability.</p>
 
         introduced our project and the field of synthetic biology to the general public and together explored issues related to safety, ethics and sustainability.</p>
 
         <br>
 
         <br>
−
         <p><button><https://2017.igem.org/Team:ETH_Zurich/Human_Practices" class="more">Human Practices</a></button></p>
+
         <p><a href="https://2017.igem.org/Team:ETH_Zurich/Human_Practices" class="more">HUMAN PRACTICES</a></p>
 
     </div>
 
     </div>
 
</section>
 
</section>
Line 151: Line 158:
 
<section>
 
<section>
 
     <div class="team">
 
     <div class="team">
 +
<figure class="team">
 +
    <img src="https://static.igem.org/mediawiki/2017/e/ec/T--ETH_Zurich--teamlanding.png">
 +
</figure>
 
     <h1>TEAM</h1>
 
     <h1>TEAM</h1>
 
         <p>We are an interdisciplinary team of eight master students of ETH Zürich who compete in the iGEM championship against hundreds of other teams from all over the world.</p>
 
         <p>We are an interdisciplinary team of eight master students of ETH Zürich who compete in the iGEM championship against hundreds of other teams from all over the world.</p>
 
         <br>
 
         <br>
−
         <p><button><a href="https://2017.igem.org/Team:ETH_Zurich/Members" class="more">Team</a></button></p>
+
         <p><a href="https://2017.igem.org/Team:ETH_Zurich/Team" class="more">TEAM</a></p>
 
     </div>
 
     </div>
 
</section>
 
</section>
  
−
 
−
<script>
 
−
$(document).ready(function(){
 
−
 
 
−
  var mousePos = {};
 
−
 
−
function getRandomInt(min, max) {
 
−
  return Math.round(Math.random() * (max - min + 1)) + min;
 
−
}
 
−
 
 
−
  $(window).mousemove(function(e) {
 
−
    mousePos.x = e.pageX;
 
−
    mousePos.y = e.pageY;
 
−
  });
 
−
 
 
−
  $(window).mouseleave(function(e) {
 
−
    mousePos.x = -1;
 
−
    mousePos.y = -1;
 
−
  });
 
−
 
 
−
  var draw = setInterval(function(){
 
−
    if(mousePos.x > 0 && mousePos.y > 0){
 
−
     
 
−
      var range = 15;
 
−
     
 
−
      var color = "background: rgb("+getRandomInt(0,255)+","+getRandomInt(0,255)+","+getRandomInt(0,255)+");";
 
−
     
 
−
      var sizeInt = getRandomInt(10, 30);
 
−
      size = "height: " + sizeInt + "px; width: " + sizeInt + "px;";
 
−
     
 
−
      var left = "left: " + getRandomInt(mousePos.x-range-sizeInt, mousePos.x+range) + "px;";
 
−
     
 
−
      var top = "top: " + getRandomInt(mousePos.y-range-sizeInt, mousePos.y+range) + "px;";
 
−
 
−
      var style = left+top+color+size;
 
−
      $("<div class='ball' style='" + style + "'></div>").appendTo('#wrap').one("webkitAnimationEnd mozAnimationEnd MSAnimationEnd oanimationend animationend", function(){$(this).remove();});
 
−
    }
 
−
  }, 1);
 
−
});
 
−
 
−
</script>
 
  
 
</main>
 
</main>

Latest revision as of 14:06, 14 December 2017

WHY

Cancer kills over 8 million people every year. That's as much as the entire population of Switzerland!

We need more specific therapies because current approaches result in many side-effects. That's why we invented CATE, the first all-in-one living cancer therapeutic with an integrated two-step safety mechanism.

A living cure to a living disease!


BACKGROUND



VISION

To tackle the challenge of treating cancer, we decided to look beyond classical approaches and from the point of view of a synthetic biologist.

Our search led us to the concept of bacterial cancer therapy.


STORY OF CATE

 

CATE consists of the non-pathogenic bacterium E. coli Nissle that has the intrinsic ability to home preferentially in tumors.

It features two safety checkpoint mechanisms to ensure only tumor cells are damaged.

CATE is administered intravenously, travels through the blood and colonizes tumors. When enough bacteria have accumulated in the tumor, they make themselves visible and start preparing the cytotoxic payload.

After imaging the tumor with MRI, the doctor can then activate the release of the cancer-killing payload.


CATE IN ACTION

 



To achieve all these novel functions, we designed a genetic circuit that is distributed over two synthetic DNA sequences.

All functions were tested and optimized to make the resulting circuit as safe and well-characterized as possible.


CIRCUIT


ENGINEERING

We increased the understanding of the system's underlying mathematics by simulating its behavior with our models.

The models were then used to define important questions to clarify in experiments and develop efficient experimental and genetic design strategies.


DRY LAB


Experimentally, we collected data to support and refine our models and to show that our system works.


WET LAB

ACHIEVEMENTS

We could experimentally confirm the predictions of the models. After testing every function individually, we combined them one after the other in milestone experiments to show the system in action.

We created and characterized new BioBrick parts as a contribution for the synthetic biology community.


ACHIEVEMENTS

HUMAN PRACTICES

We went beyond the lab and reached out to experts to better understand current technological and safety issues in order to enhance the design of our project.

Further, we introduced our project and the field of synthetic biology to the general public and together explored issues related to safety, ethics and sustainability.


HUMAN PRACTICES

TEAM

We are an interdisciplinary team of eight master students of ETH Zürich who compete in the iGEM championship against hundreds of other teams from all over the world.


TEAM